Attorney Docket No.: 4318.224-US

## BEST AVAILABLE COPI

**PATENT** 

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Bisgaard-Frantzen et al.

Confirmation No: 7527

Serial No.: 09/902,188

Group Art Unit: 1751

Filed: July 10, 2001

Examiner: To be assigned

For: Amylase Variants

**Commissioner for Patents** 

Washington, DC 20231

#### **AMENDMENT FEE TRANSMITTAL**

RECEIVED

JAN 1 0 2002

TC 1700

Sir:

Transmitted herewith is an Amendment for the above-identified application. No additional claims fee is required.

Respectfully submitted,

Date: October 25, 2001

Jason I. Garbell, Reg. No. 44,116 Novozymes North America, Inc. 405 Lexington Avenue, Suite 6400 New York, NY 10174-6401

(212) 867-0123

811751

Q JA TO ARTONNE

rney Docket No.: 4318.224-US

**PATENT** 

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

re Application of: Bisgaard-Frantzen et al.

Confirmation No: 7527

Serial No.: 09/902,188

Group Art Unit: 1751

Filed: July 10, 2001

Examiner: To be assigned

For: Amylase Variants

BEST AVAILABLE COPY

#### **CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)**

Commissioner for Patents Washington, DC 20231

•

Sir:

RECEIVE JAN 1 0 2002
TC 1700

I hereby certify that the attached correspondence comprising:

- 1. Preliminary Amendment
- 2. Amendment Fee Transmittal (in duplicate)

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents Washington, DC 20231

on October 25, 2001.

Julie Tabarovsky
(name of person mailing paper)

gnature of person mailing paper



# BEST AVAILABLE COPY

PATENT

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Bisgaard-Frantzen et al. Confirmation No: 7527

Serial No.: 09/902,188

Group Art Unit: 1751

Filed: July 10, 2001

Examiner: To be assigned

For: Amylase Variants

PRELIMINARY AMENDMENT

RECEIVED

JAN 1 0 2002

Commissioner for Patents Washington, DC 20231

TC 1700

Sir:

Before examination, please amend the above-identified application as follows:

#### IN THE CLAIMS:

Please cancel claims 1-29 without prejudice or disclaimer.

Please add new claims 30-49, as follows:

- 30. A variant of a parent alpha-amylase, which displays at least 80% homology with SEQ ID No. 3 and which has one or more of the following amino acid substitutions K107R, K177R, K237R, K240R, D162N, D186N, D190N, D197N, D203N, D205N, D207N, E188Q, and E192Q.
- 31. A DNA construct comprising a DNA sequence encoding an alpha-amylase variant according to claim 30.
- 32. A recombinant expression vector which carries a DNA construct according to claim 31.
- 33. A cell which is transformed with a DMA construct according to claim 31.
- 34. A cell according to claim 33, which is a microorganism.
- 35. A cell according to claim 33, which is a bacterium or a fungus.